TriangleDenikitug (NCT07527858)
Denikitug trial for Advanced Microsatellite Stable Colorectal Cancer (NCT07527858). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced microsatellite-stable colorectal adenocarcinoma that progressed after treatment. At most two prior systemic treatment lines are allowed; required previous drugs depend on their indication. Appendix cancer is excluded.
The idea: denikitug targets CCR8-positive regulatory T cells that suppress immune attack. Randomized groups test it alone, with nivolumab, or with trifluridine-tipiracil plus bevacizumab. Another group receives trifluridine-tipiracil plus bevacizumab alone. Researchers measure tumor response and safety.
This phase 2 study plans 170 patients. Gilead sponsors it, with four recruiting US sites. Prior immuno-oncology treatment is excluded.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.